Proliferation of Novel Cell Type Platforms in the Oncology Competitive Landscape-Part II
Perhaps more so than any other modality to date, cancer cell therapies have captured the imaginations and wherewithal of industry,...
Joel Sandler's Passles
Proliferation of Novel Cell Type Platforms in the Oncology Competitive Landscape-Part 1
Perhaps more so than any other modality to date, cancer cell therapies have captured the imaginations and wherewithal of industry,...
Innovation in a Buyer’s Market: Standing out in an Increasingly Crowded and Diversified Cancer Treatment Algorithm (a Cancer Progress contribution)
Imagine being told that you are about to be dropped into a deep and deadly hole with nothing but a grappling hook to pull yourself out....
CD19 and BCMA – “What if This is as Good as it Gets?”
I’m no fortune-teller. But I can predict with a reasonable amount of certainty that, in the next week or so, we’ll see a press...
‘Allo There!’ – Accommodation of a Less-Than-Stellar TPP for Allo Cell Therapy in the Oncology Landscape
As we leap into the new decade, anyone who has a stake in oncology drug development has to be keeping an eye or two on the rapidly...
As a free user, you can follow Passle and like posts.
To repost this post to your own Passle blog, you will need to upgrade your account.
For plans and pricing, please contact our sales team at sales@passle.net